HGH 100iu (Somatropin)

Description

Overview

HGH 100iu (Somatropin) is a recombinant human growth hormone (rhGH) reference material supplied by G Peptide Labs strictly for in-vitro and preclinical laboratory research. Somatropin is a single-chain, 191-amino-acid polypeptide (approximately 22.1 kDa) whose primary sequence is identical to the dominant pituitary growth hormone isoform. Each vial is lyophilised, non-glycosylated protein manufactured by recombinant DNA expression and characterised for identity and purity. This listing is intended for qualified research organisations and is not for human or veterinary use, diagnostic use, or consumption of any kind.

Research Context

Growth hormone occupies a central position in the somatotropic axis, and recombinant somatropin has become a standard tool compound for investigators studying that axis in controlled laboratory settings. Because its sequence matches the native molecule, it is widely used as a well-defined ligand in cell-based assays and in preclinical animal-model studies where researchers characterise growth-factor signalling, receptor pharmacology, and downstream transcriptional responses.

• Cell-culture investigations of growth hormone receptor (GHR) binding and activation.
• Preclinical animal-model work examining hepatic induction of insulin-like growth factor 1 (IGF-1) and the wider somatotropic cascade.
• Analytical and structural characterisation studies, including purity, isoform, and aggregation profiling of recombinant protein preparations.

All described applications refer exclusively to laboratory research. G Peptide Labs makes no representation regarding any physiological effect in humans and offers no therapeutic, performance, or health claims.

Mechanism of Interest

In the published research literature, somatropin is described as engaging the growth hormone receptor, a constitutively dimerised cytokine-family receptor. Ligand engagement is associated with reorientation of the receptor and activation of the receptor-associated Janus kinase 2 (JAK2), which in turn phosphorylates STAT5a and STAT5b to drive transcriptional programmes. A principal downstream readout studied in preclinical models is the induction of IGF-1, frequently used by researchers as a signalling endpoint in receptor and pathway experiments. These mechanistic points are provided as scientific background for in-vitro investigation only and do not describe any use in people.

Specifications

• Compound: Somatropin (recombinant human growth hormone, rhGH)
• Sequence length: 191 amino acids, single chain
• Molecular formula: C990H1528N262O300S7
• Molecular weight: ~22,124 Da (approx. 22.1 kDa)
• CAS number: 12629-01-5
• Disulfide bonds: Cys53-Cys165 and Cys182-Cys189
• Labelled potency: 100 IU per vial (rhGH conversion approx. 3 IU/mg)
• Physical form: White lyophilised powder
• Purity: Verified by third-party analysis; see the certificate of analysis for the specific lot
• Intended use: Research use only (RUO)

Handling / Reconstitution / Storage

Recombinant proteins are sensitive to heat, agitation, and repeated freeze-thaw. Researchers typically observe the following handling practices in the laboratory:

• Store the sealed lyophilised vial refrigerated at 2-8 °C for short-term holding, or at -20 °C for extended storage, protected from light.
• Reconstitute with an appropriate sterile diluent (for example bacteriostatic or sterile water) added gently down the vial wall; avoid vigorous shaking or foaming, which can denature the protein.
• Allow the powder to dissolve slowly and swirl gently rather than vortexing.
• After reconstitution, keep the solution at 2-8 °C and aliquot to minimise freeze-thaw cycles; discard according to your laboratory’s protocols.
• Handle using standard laboratory safety practices, including appropriate personal protective equipment.

Quality & Verification

Every lot is accompanied by a third-party certificate of analysis (COA) so that receiving laboratories can independently confirm what they are working with before beginning an experiment. Analytical characterisation for recombinant somatropin commonly includes reversed-phase and size-exclusion HPLC for purity and aggregation, mass spectrometry for identity, and appropriate content assays. G Peptide Labs recommends reviewing the lot-specific COA and correlating the reported identity, purity, and molecular-weight data with your own inbound quality checks.

Research use only. This product is supplied to qualified researchers and institutions in Canada for laboratory investigation. It is not a medicine, supplement, or food, and nothing in this description should be interpreted as guidance for use in humans or animals.

Selected Research

Peer-reviewed references provided for scientific context; they describe laboratory and preclinical findings only.

1. Somatropin and its variants: structural characterization and methods of analysis. Pharmeuropa Bio Bayol A, Bristow A, Charton E, Girard M, Jongen P (2004). PMID: 15659284
2. A new mechanism for growth hormone receptor activation of JAK2, and implications for related cytokine receptors. JAK-STAT Waters MJ, Brooks AJ, Chhabra Y (2014). PMID: 25101218
3. IGF-I receptor signalling: lessons from the somatotroph. Recent Progress in Hormone Research Melmed S, Yamashita S, Yamasaki H, Fagin J, Namba H, Yamamoto H, Weber M, Morita S, Webster J, Prager D (1996). PMID: 8701079
4. Current research on recombinant human growth hormone and the related growth factors, IGF-1 and GRF. Acta Paediatrica Scandinavica. Supplement Fryklund L (1986). PMID: 3109208